Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Anne Jouinot

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

A. Jouinot1, B. Royer2, S. Moeung3, E. Chatelut3, A. Bellesoeur4, G. Assié5, A. Thomas-Schoemann6, J. Bertherat5, F. Goldwasser4, B. Blanchet6

Author affiliations

  • 1 Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, 75014 - Paris/FR
  • 2 Clinical Pharmacology And Toxicology Dpt, CHU Besancon, Besancon/FR
  • 3 Institut Claudius-regaud, Université de Toulouse, INSERM, Centre de Recherches en Cancérologie de Toulouse, Toulouse/FR
  • 4 Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris/FR
  • 5 Endocrinology, Center For Rare Adrenal Diseases, Cochin Hospital, Paris Descartes University, AP-HP, Paris/FR
  • 6 Clinical Pharmacology, Cochin Hospital, Paris Descartes University, AP-HP, Paris/FR
More

Resources

Abstract 2905

Background

Association between mitotane and platinum-etoposide chemotherapy is the front-line treatment in metastatic adrenocortical carcinoma (ACC), although this regimen shows limited efficacy. Drug-drug interaction between mitotane -which is a strong pharmacokinetic inductor of CYP3A4 and BRCP- and etoposide –which is a substrate of CYP3A4 and BRCP- may contribute to chemoresistance in ACC. The aim of this study was to evaluate the pharmacokinetic interaction between mitotane and etoposide.

Methods

From December 2016 to October 2017, this observational study included 5 consecutive ACC patients treated with platinum-etoposide (120 to 150 mg/m2 J1-J2-J3 at cycle 1) chemotherapy in referral center for rare adrenal diseases and oncology department of Cochin hospital, Paris. Plasma etoposide concentrations were measured using liquid chromatography at 0, 4 and 24h after each etoposide infusion. In the absence of dose-limiting toxicity, a dose escalation of etoposide was proposed from cycle 2.

Results

Patients received a median of 3 [2 to 6] chemotherapy cycles, in association with mitotane (4 patients, median mitotane plasma concentration of 14.2 mg/L) or after mitotane discontinuation (1 patient, plasma concentration 1 mg/L). Etoposide clearance was higher in association with mitotane (4.95 L/h [2.67 to 6.20]) than after discontinuation (2.53 L/h [2.02 to 2.78], Wilcoxon p = 0.014) or in a reference population not treated with mitotane (1.81 L/h)1. Etoposide dose escalation was performed in 4 patients treated with mitotane, resulting in 2 minor tumor response at 300mg/m2 and 1 febrile neutropenia.

Conclusions

Drug-drug interaction between mitotane and etoposide may partly explain the low efficacy of platinum-etoposide chemotherapy in ACC. Given the elimination half-life of mitotane is extremely long (18-159 days), this observation suggests further a potential benefit of increasing etoposide dosage in patients receiving mitotane than stopping mitotane before chemotherapy initiation in ACC patients.

Clinical trial identification

Legal entity responsible for the study

Blanchet Benoit and Jouinot Anne.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings